PMID- 22420602
OWN - NLM
STAT- MEDLINE
DCOM- 20121130
LR  - 20131121
IS  - 1526-4637 (Electronic)
IS  - 1526-2375 (Linking)
VI  - 13 Suppl 1
DP  - 2012 Mar
TI  - Efficacy and safety of dual-opioid therapy in acute pain.
PG  - S12-20
LID - 10.1111/j.1526-4637.2012.01330.x [doi]
AB  - BACKGROUND: Although opioids are widely accepted as standard therapy for treating 
      acute postoperative pain, the frequent occurrence of adverse events (AEs) and the 
      substantial burden on the patient and the costs of care are a barrier to optimal 
      dosing and adherence to prescribed treatment. Coadministration of two opioids is 
      not often recommended as a multimodal treatment option for moderate to severe 
      acute pain because of lack of knowledge about the potential benefit of such 
      combinations and due to potential concerns about side effects and doubts about 
      the added benefits. Study results on the coadministration of two or more opioids 
      demonstrate synergistic analgesia with a similar or lower incidence of 
      opioid-related AEs. One such combination is morphine and oxycodone. SUMMARY: 
      Moxduo(R) (morphine/oxycodone 3/2) is a dual-opioid combination of morphine and 
      oxycodone used to treat acute pain. Independent controlled studies of the 
      coadministration of morphine plus oxycodone demonstrate excellent analgesia with 
      a lower incidence or less-intense AEs, especially nausea and vomiting, compared 
      with equianalgesic doses of individual opioids. Controlled trials with 
      morphine/oxycodone 3/2 have enrolled approximately 1,500 subjects with moderate 
      to severe post-surgical pain who received multiple doses of morphine/oxycodone 
      3/2 or single-entity opioids for a maximum of 23 days. These phase 2 and phase 3 
      clinical studies demonstrate analgesic efficacy that is at least comparable to 
      the individual components and showing a 50-75% reduction in moderate to severe 
      AEs, especially nausea and vomiting. CONCLUSION: Thus, the dual-opioid 
      combination product, morphine/oxycodone 3/2, compared with equianalgesic 
      monotherapy doses of oxycodone or morphine may provide effective relief of 
      moderate or severe post-surgical pain, while reducing the impact of AEs on 
      patients and prescribers.
CI  - Wiley Periodicals, Inc.
FAU - Webster, Lynn
AU  - Webster L
AD  - Lifetree Clinical Research, Salt Lake City, Utah 84106-6102, USA. 
      lrwebstermd@gmail.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Pain Med
JT  - Pain medicine (Malden, Mass.)
JID - 100894201
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Drug Combinations)
RN  - 0 (MoxDuo)
RN  - 76I7G6D29C (Morphine)
RN  - CD35PMG570 (Oxycodone)
SB  - IM
MH  - Acute Pain/*drug therapy/metabolism/physiopathology
MH  - Analgesics, Opioid/*administration & dosage/adverse effects
MH  - Drug Combinations
MH  - Drug Synergism
MH  - Humans
MH  - Morphine/*administration & dosage/adverse effects
MH  - Oxycodone/*administration & dosage/adverse effects
EDAT- 2012/03/21 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/03/17 06:00
PHST- 2012/03/17 06:00 [entrez]
PHST- 2012/03/21 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - 10.1111/j.1526-4637.2012.01330.x [doi]
PST - ppublish
SO  - Pain Med. 2012 Mar;13 Suppl 1:S12-20. doi: 10.1111/j.1526-4637.2012.01330.x.